Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Autor:	Jonathan W. Friedberg, Jasmine Zain, Jeffrey Matous, Andrei R. Shustov, Nancy L. Bartlett, Robert T. Chen, Michelle A. Fanale, Andres Forero-Torres, Megan M. O'Meara, Scott E. Smith, Anas Younes, Ajay K. Gopal
Rok vydání:	2014
Předmět:	Adult Male Cancer Research medicine.medical_specialty Immunoconjugates Adolescent Lymphoma Anemia Population Ki-1 Antigen Antineoplastic Agents Young Adult Refractory Internal medicine medicine Humans Child education Brentuximab vedotin Adverse effect Anaplastic large-cell lymphoma Aged Retrospective Studies Aged 80 and over Brentuximab Vedotin education.field_of_study business.industry Age Factors Hematology Middle Aged medicine.disease Surgery Clinical trial Treatment Outcome Oncology Concomitant Female Neoplasm Recurrence Local business medicine.drug
Zdroj:	Leukemia & Lymphoma. 55:2328-2334
ISSN:	1029-2403 1042-8194
Popis:	Older adults constitute a significant proportion of the cancer population, but are underrepresented in clinical trials. We conducted a retrospective analysis of the safety and efficacy of brentuximab vedotin in adults ≥ 60 years with relapsed CD30-positive lymphomas. Baseline characteristics and safety data were compared for older (median age 66) and younger patients (60 years, median age 32). Exposure to brentuximab vedotin was comparable. Older patients had more preexisting conditions (median 11 vs. 6) and were receiving more concomitant medications (median 7.5 vs. 4). Higher rates of anemia (30% vs. 10%), peripheral sensory neuropathy (60% vs. 46%), fatigue (58% vs. 43%) and adverse events ≥ grade 3 (70% vs. 56%) occurred in older patients. Objective response rates were 56% and 100% in older patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma, respectively. With appropriate monitoring, brentuximab vedotin may represent a meaningful clinical option for older patients with relapsed CD30-positive lymphomas.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94088ce8c6f8c142bc09134f0aee8d48 https://doi.org/10.3109/10428194.2013.876496 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.